timmins

Jonathan Timmins

Associate Director, Business Development

Business Development
About

Jonathan Timmins is a Business Development Manager at Quotient Sciences, where he plays a key role in supporting pharmaceutical and biotech partners as they navigate early‑phase drug development. With a strong scientific foundation and a passion for innovative problem‑solving, Jonathan is responsible for identifying new business opportunities, building meaningful client relationships, and progressing programmes that align with Quotient’s integrated drug product and clinical service offerings.

Leveraging experience gained over more than two years within Quotient’s commercial organisation, Jonathan works closely with customers to understand their development challenges and connect them with the right solutions - whether that involves standalone drug product formulation, clinical services, or the efficiencies of Quotient’s Translational Pharmaceutics® platform. His ability to interpret complex requirements and translate them into clear, actionable pathways helps clients streamline timelines and move forward with confidence.

Jonathan holds a Bachelor’s degree in Biochemistry from the University of Liverpool. His blend of scientific knowledge, commercial acumen, and commitment to improving patient outcomes enables him to provide insightful, expert guidance to companies progressing their molecules from first‑in‑human through early clinical development and beyond.

Quotient Sciences Translational Pharmaceutics
Translational Pharmaceutics, Drug Product Optimization, First-in-Human, Human ADME

Translational Pharmaceutics® Integrated Drug Development Info Sheet

10 March 2025 Read More

Latest news from Quotient Sciences

More News
News & Announcements, Nottingham, UK, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline By: Dr. Andrew Lewis
Read More
News & Announcements, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences shortlisted for "Best Use of AI in Clinical Development & Trial Innovation" at the Scrip Awards 2026 By: Dr. Andrew Lewis
Read More